Celebrating National Nutrition Month: FriskaAi Unveils Free Version of its Innovative Nutrition Tool
ARLINGTON, VA / ACCESS Newswire / March 25, 2025 / FriskaAi, a groundbreaking healthcare platform that leverages advanced AI and mobile technology to empower individuals to take control of their health journey in partnership with their physician, has launched a slimmed-down version of its Friska NutriAi platform revolutionizing nutrition and wellness through the power of AI. Available at no cost to consumers, this special version of Friska's nutrition management tool provides personalized dietary guidance to enhance well-being, manage chronic diseases, and optimize health outcomes.
'March is National Nutrition Month and the perfect time to highlight nutrition's crucial role in overall health and wellness, impacting everything from physical development and disease prevention to mental wellbeing. Good nutrition enhances productivity, learning, and emotional well-being, making it the cornerstone of a healthy lifestyle,' says FriskaAi CEO Shaji Nair. 'Friska NutriAi is a convenient and effective way to plan healthy meals and optimize daily nutrition to achieve various health goals, all backed by the latest research and dietary expertise.'
Built on the latest advancements in nutritional science, AI, and health analytics, Friska NutriAi represents the collaborative efforts of leading dietitians, physicians, and data scientists to ensure that every recommendation is backed by credible research. The free version can be accessed at https://friskanutriai.com/. Users create an account and answer several questions about their medical history, lifestyle, and dietary preferences and habits. Powerful AI algorithms analyze the information and generate customized nutrition plans tailored to their specific goals.
'Healthy eating doesn't have to be complicated. Friska NutriAi makes it easy for anyone who wants to take their nutrition to the next level, regardless of where they are on their health journey,' says Fjorino Musaku, M.Ed, CDCES, professor at Henry Ford College and nutrition expert with FriskaAi. 'Customized meal plans consider any dietary restrictions, allergies, and medical conditions to recommend foods that support individual health and wellness goals.'
AI-Powered Nutrition Support
The comprehensive version of Friska NutriAi leverages advanced AI algorithms to provide individuals with evidence-based, actionable nutrition recommendations based on real-time data and health analytics. Backed by nutritionists and healthcare professionals, Friska NutriAi supports individuals with chronic conditions requiring dietary adjustments, such as diabetes, hypertension, and high cholesterol. It is also ideal for anyone seeking weight management support, optimal nutrition guidance, or age-appropriate dietary recommendations for longevity and wellness.
'Designed to meet comprehensive nutrition needs, Friska NutriAi helps physicians and other clinicians provide patients with personalized nutrition support. For consumers, it helps athletes and fitness enthusiasts optimize performance through nutrition and is an easy, convenient, and healthy meal planning solution,' says Nair.
The platform, which syncs with wearable devices and EHR systems for a comprehensive health overview, provides:
Meal planning and recipes that accommodate dietary preferences.
Nutritional coaching with certified nutritionists.
Smart grocery lists based on NutriAi-generated meal plans.
AI-driven food recommendations based on taste preferences and health goals.
Micronutrient tracking ensures balanced nutrition by monitoring essential vitamin and mineral intake.
Allergy and intolerance customization to accommodate dietary restrictions and allergies.
Family meal planning that simplifies meal prep with tailored plans catering to the household's needs and preferences.
Physician-Directed Mobile Wellness
Friska NutriAi is part of FriskaAi, a powerful AI-enabled EHR-agnostic platform that can address up to 80% of chronic diseases, including diabetes and obesity, by helping providers take an evidence-based approach to preventive care. It leverages advanced AI and mobile technology to generate personalized health insights and recommendations, empowering patients to take control of their health journey in partnership with their clinical team.
Enrollment in FriskaAi is initiated through the physician's office, ensuring seamless integration into the healthcare experience. Once enrolled, patients use the FriskaAi mobile app to track health data, communicate with the practice, and receive personalized health insights and wellness plans. The powerful, HIPAA-compliant FriskaAi duo securely collects and analyzes vast amounts of clinical data and studies supplemented by information from the patient's smart devices and health apps.
When FriskaAi is integrated with the practice's EHR or practice management system, the data is stored directly in the patient's EMR to help inform care decisions. Data is continuously monitored and analyzed by sophisticated AI-powered algorithms that alert the patient when action is recommended and generate actionable reports for use by the clinician at the point of care. Aggregated health data is also analyzed to help physicians identify patient population health trends and risks, enabling preventive care strategies and interventions.
'FriskaAi helps physicians who are interested in adding aspects of preventive or lifestyle medicine into their care plans provide patients with mobile access to robust and holistic health tools that bring together wellness plans that address chronic conditions and achieve desired health outcomes,' says Nair.
About FriskaAi
FriskaAi is a powerful AI-enabled EHR-agnostic platform that helps physicians and other providers take an evidence-based approach to preventive care. The physician-initiated platform leverages advanced AI- and mobile technology to provide patients with personalized health insights and recommendations, empowering them to take control of their health journey in partnership with their clinical team. This aggregated health data, including information from patients' glucometers, other smart devices, and health apps, is continuously analyzed by advanced evidence-based algorithms that alert the patient when action is needed and provide clinicians with actionable reports to inform care decisions. FriskaAi also supports population health strategies by analyzing aggregated health data to identify trends and risks within a defined patient population. For more information, visit: www.friska.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 hours ago
- Associated Press
ASCP and NCPA Announce Joint Recommendations to Manufacturers to Effectuate Medicare's Maximum Fair Price (MFP)
ALEXANDRIA, VA / ACCESS Newswire / June 13, 2025 / The American Society of Consultant Pharmacists (ASCP) and the National Community Pharmacists Association (NCPA) have announced joint recommendations to pharmaceutical manufacturers aimed at helping to support pharmacies facing material cash flow concerns under Medicare's Drug Price Negotiation Program (MDPNP). The two organizations, both of which represent pharmacists committed to high-quality care for all patients including Medicare beneficiaries, expressed concerns about the impact of the MFP, which is part of the Medicare Drug Price Negotiation Program (MDPNP). This was included in the Inflation Reduction Act of 2022 and enables Medicare to directly negotiate the prices of certain single-source medications without generic or biosimilar competition. CMS selected 10 drugs for an initial round of negotiations in 2023. These included medications for diabetes, heart failure, and peripheral artery disease. These negotiated prices, the highest that a Medicare Part D beneficiary or plan sponsor will have to pay for targeted medications, are slated to go into effect on January 1, 2026. While ASCP and NCPA fully support ensuring fair medication prices for Medicare beneficiaries, an analysis conducted for NCPA found that under MFP, pharmacies may face manufacturer refund payment delays of more than 21 days, beyond the 14-day Medicare prompt pay standard. At the same time, pharmacies could lose nearly $11,000 in weekly cash flow and $43,000 annually. Over 93% of independent pharmacies surveyed by NCPA state they may not be able to stock some medications targeted for price reductions because of cash flow and reimbursement below cost; and most LTC pharmacies anticipate closures, staff layoffs, service reductions, and medications shortages stemming from the MDPNP. Pharmacists at greatest risk for these negative impacts include sole proprietors in rural and urban areas, pharmacies that heavily rely on prescription revenue, and long-term care pharmacies. To address these concerns, ASCP and NCPA made several key recommendations to manufacturers, including the following: 'Most independent pharmacies and long-term care pharmacies care for populations that are heavily dependent on Medicare. It's critical that they are compensated in a fair and timely manner. Otherwise, they will face massive cash-flow problems and not be able to provide prescription services to their Medicare patients. A recent NCPA survey found that 93 percent of independent pharmacists would consider opting out of the program unless those concerns are addressed. That would be a disaster for Medicare beneficiaries and the program itself,' said Doug Hoey, NCPA's CEO. 'The IRA presents unprecedented threats to long-term care pharmacy as well as new opportunities to build a constructive, transactional relationship between pharmacists and manufacturers,' said Chad Worz. 'In developing and presenting these recommendations, we are hoping to send a fair and equitable framework that rekindles the historical partnership between pharmaceutical manufacturers and pharmacies. This, first and foremost, benefits patients while also protecting the sustainability of pharmacies and innovators. We look forward to continuing our constructive conversations with impacted manufacturers.' ASCP and NCPA urge manufacturers to incorporate these recommendations into their MFP effectuation plans by September 1, 2025, ensuring pharmacies remain viable and patients retain access to essential medications. About ASCP: The American Society of Consultant Pharmacists (ASCP) is the only international professional society devoted to optimal medication management and improved health outcomes for all older persons. ASCP's members manage and improve drug therapy and improve the quality of life of geriatric patients and other individuals residing in a variety of environments, including nursing facilities, sub-acute care and assisted living facilities, psychiatric hospitals, hospice programs, and home and community-based care. About NCPA: Founded in 1898, the National Community Pharmacists Association is the voice for the community pharmacist, representing over 18,900 pharmacies that employ more than 205,000 individuals nationwide. Community pharmacies are rooted in the communities where they are located and are among America's most accessible health care providers. Contact Information Melissa Blacketer Senior Director of Communications [email protected] 703-739.1311 SOURCE: ASCP press release
Associated Press
a day ago
- Associated Press
WellBalance to Present Three Sessions at the 2025 IPPA World Congress in Brisbane, Australia
Includes Workshop to Train Coaches and Therapists to Use the WellBalance Model with Clients LAGUNA NIGUEL, CA / ACCESS Newswire / June 12, 2025 / WellBalance is honored to announce its selection to present three sessions at the upcoming International Positive Psychology Association's (IPPA) World Congress, taking place in Brisbane, Australia, July 2-5, 2025. Recognized as the premier global gathering of scientists and practitioners in the field of positive psychology, the IPPA World Congress spotlights cutting-edge approaches to promoting flourishing, resilience, and wellbeing across World Congress 2025 Among hundreds of submissions, three WellBalance abstracts were accepted across diverse formats - including one of only a few workshops offered at the Congress, to train coaches and therapists on the practical application of the WellBalance Model. This high-profile opportunity allows WellBalance to showcase the growing real-world impact of its evidence-based framework for personalized wellbeing design and will form the basis of future of certifications to use the WellBalance Assessment with clients. WellBalance's presentations include: 'This is a tremendous milestone for our team,' said Troy Norris, Founder and Principle Investigator of the WellBalance Institute for Positive Wellbeing. 'To be chosen for multiple presentations - and especially to lead a hands-on workshop for coaches and therapists - demonstrates the relevance, scientific rigor, and practical value of the WellBalance approach to advance the field of positive psychology toward real-world application.' The WellBalance Model and Assessment is a validated psychological measure of positive wellbeing, integrating feelings of wellbeing with lived experiences, to help individuals, coaches, and organizations identify meaningful growth areas and implement tailored, actionable wellbeing plans. The model has been highlighted in peer-reviewed publications in Frontiers in Psychology, Frontiers in Psychiatry, and Advances in the Psychology of Well-Being. This latest recognition by IPPA reinforces WellBalance's commitment to develop practical, science-based strategies to translate the latest science of positive psychology and wellbeing into actionable insights to create more flourishing lives, relationships and workplaces. By integrating validated wellbeing measures with a structured intervention framework, the WellBalance Model of Positive Wellbeing offers individuals, coaches, therapists and employers a practical and personal way to improve positive wellbeing. To learn more about the IPPA World Congress, visit: To explore the science behind the WellBalance Model, visit: Contact InformationTroy Norris Chief Wellbeing Officer SOURCE: WellBalance, LLC press release
Associated Press
a day ago
- Associated Press
Zentek Announces Test Results Validating ZenGUARD(TM) Enhanced Air Filters as a High-Performance Solution for ASHRAE Standard 241 Compliance
GUELPH, ON / ACCESS Newswire / June 12, 2025 / Zentek Ltd. ('Zentek' or the 'Company') (Nasdaq:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company, is pleased to announce new independent test results comparing the viral filtration efficiency ('VFE') of ZenGUARD™ Enhanced Air Filters against the bacteriophage MS2 compared to equivalent Minimum Efficiency Reporting Value ('MERV')-rated filters without ZenGUARD™. The testing was performed by the third-party ISO 17025:2017 certified lab LMS Technologies Inc. ('LMS'), which specializes in the testing and certification of filter manufacturers across the world in line with American Society of Heating, Refrigerating and Air-Conditioning Engineers ('ASHRAE') standards. Test Results ZenGUARD™ Enhanced Air Filters achieved an average infectious aerosol removal efficiency (εPR) of MS2 bacteriophage of 42% compared to an untreated filter, which achieved an average εPR of 16%. These strong results align with previous tests performed with bacteriophage Phi6, which is often used as a surrogate for SARS-CoV-2 and other enveloped viruses. This milestone adds to a growing body of third-party validation demonstrating ZenGUARD™ Enhanced Air Filter's unique combination of effectiveness and simplicity. To highlight this, the Company believes ZenGUARD™ Enhanced Air Filters are the only technology that can accomplish the following simultaneously: Highly effective at controlling infectious aerosol in line with ASHRAE 241 Achieve this without an increase in pressure drop, energy consumption and carbon emissions Work with existing heating, ventilation, and air conditioning units Not require any additional equipment Extend filter life and reduce changeout frequency compared to more dense filters reducing labour and waste disposal costs ASHRAE Standard 241-2023: Control of Infectious Aerosols ASHRAE Standard 241 is new guidance designed to help buildings reduce the spread of airborne viruses, like SARS-CoV-2, influenza, and other respiratory illnesses. It sets clear guidelines for Equivalent Clean Airflow ('ECA') (from ventilation, filtration, or air cleaning) that is needed to lower the risk of infection in indoor spaces. This is important because it gives schools, offices, and other public buildings a science-based way to improve indoor air quality and the health of building occupants. ASHRAE 241 focuses specifically on health and infection control, making it a key tool for creating safer indoor environments. The standard includes the use of MS2 bacteriophage as a standardized surrogate for evaluating the control of infectious aerosol. Its inclusion ensures a consistent benchmark for assessing the effectiveness of technologies such as ZenGUARD™ Enhanced Air Filters. Based on these new test results using MS2 bacteriophage, the Company now has science-based, directly comparable data demonstrating that ZenGUARD™ is highly effective at controlling infectious aerosols and is fully aligned with ASHRAE Standard 241 testing methodology. ZenGUARD™'s higher εPR translates to a higher ECA, making it a practical and effective option for inclusion in building readiness plans prepared by facility managers and building operators. Importantly, ASHRAE 241 assigns an εPR of zero to any filter rated below MERV 11A. However, ZenGUARD™, which has been independently tested with MS2, can be assigned an EPR of 42%, even when applied to a lower-rated MERV 9A filter. This allows facility managers to confidently adopt ZenGUARD™ technology without needing to upgrade to MERV 11A or higher filters, which may be incompatible with existing HVAC systems. 'These exciting new test results not only reinforce ZenGUARD™'s proven ability to improve indoor quality without increasing energy consumption - they highlight how our solution meets the requirements of ASHRAE 241, the most recent and relevant third-party guidance for controlling infectious aerosols in buildings,' said Greg Fenton, CEO of Zentek Ltd. 'Conventional panel filters - like electrostatically charged MERV 13s - are designed to trap dust and often fall short over time when it comes to impacting aerosols responsible for respiratory infections. In contrast, our filters were specifically designed to enhance mechanical filtration of infectious aerosol via the unique properties of our patented ZenGUARD™ technology - and we have now demonstrated our ability to do this in line with the only standard focused solely on infection control. As building operators face growing pressure to meet new air quality standards and carbon reduction targets, we're proud to offer our unique technology that is proven to effectively keep indoor spaces safe, while also reducing total cost of ownership and carbon emissions.' About Zentek Ltd. Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. Zentek's patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same with HVAC (heating, ventilation, and air conditioning) filters Zentek's ZenGUARD™ production facility is in Guelph, Ontario. Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets. For further information: [email protected] Ryan Shacklock Email: [email protected] 306-270-9610 To find out more about Zentek, please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at . Forward-Looking Statements This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Zentek Ltd. press release
